PubMed Health⌕ Search

PubMed · 16597671

The logistic transform for bounded outcome scores.

Abstract

The logistic transformation, originally suggested by Johnson (1949), is applied to analyze responses that are restricted to a finite interval (e.g. (0,1)), so-called bounded outcome scores. Bounded outcome scores often have a non-standard distribution, e.g. J- or U-shaped, precluding classical parametric statistical approaches for analysis. Applying the logistic transformation on a normally distributed random variable, gives rise to a logit-normal (LN) distribution. This distribution can take a variety of shapes on (0,1). Further, the model can be extended to correct for (baseline) covariates. Therefore, the method could be useful for comparative clinical trials. Bounded outcomes can be found in many research areas, e.g. drug compliance research, quality-of-life studies, and pain (and pain relief) studies using visual analog scores, but all these scores can attain the boundary values 0 or 1. A natural extension of the above approach is therefore to assume a latent score on 0,1) having a LN distribution. Two cases are considered: (a) the bounded outcome score is a proportion where the true probabilities have a LN distribution on (0,1) and (b) the bounded outcome score on [0,1] is a coarsened version of a latent score with a LN distribution on (0,1). We also allow the variance (on the transformed scale) to depend on treatment. The usefulness of our approach for comparative clinical trials will be assessed in this paper. It turns out to be important to distinguish the case of equal and unequal variances. For a bounded outcome score of the second type and with equal variances, our approach comes close to ordinal probit (OP) regression. However, ignoring the inequality of variances can lead to highly biased parameter estimates. A simulation study compares the performance of our approach with the two-sample Wilcoxon test and with OP regression. Finally, the different methods are illustrated on two data sets.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Emmanuel Lesaffre, Dimitris Rizopoulos, Roula Tsonaka. 2006-04-05. The logistic transform for bounded outcome scores.. https://doi.org/10.1093/biostatistics%2Fkxj034

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.

OBJECTIVE: To determine the best time to administer statins for optimal lowering of low-density lipoprotein cholesterol (LDL-C) by reviewing the clinical evidence evaluating the chronobiologic effects of morning versus evening statin administration. DATA SOURCES: Using the MeSH terms HMG-CoA reductase inhibitors, statins, morning and evening dosing, and clinical trials, a literature review was conducted to identify articles in MEDLINE (1966-December 2006), International Pharmaceutical Abstracts (1970-December 2006), and IOWA Drug Information Systems (1985-December 2006). DATA SYNTHESIS: Seven English-language studies evaluating morning and evening statin administration were identified and evaluated. Based on the available data, simvastatin demonstrated a pronounced LDL-C percentage reduction with evening dosing. Although not statistically significant, a trend in the LDL-C percentage reduction favoring evening statin administration was noted with lovastatin, pravastatin, and rosuvastatin. Atorvastatin demonstrated similar LDL-C reduction regardless of administration time. With the exception of simvastatin, the trials comparing morning versus evening effects of statins on LDL-C have several significant methodologic shortcomings, including small sample size, lack of statistical power, and inappropriate exclusion criteria that did not include or did not mention drug-induced effects on lipids. CONCLUSIONS: There are sufficient data to support evening administration of simvastatin to achieve optimal lowering of LDL-C levels. Rigorous and robust trials are necessary to determine the best administration time to achieve optimal LDL-C lowering for lovastatin, pravastatin, rosuvastatin, atorvastatin, and fluvastatin.

Anticholesteremic Agents↗

Will torcetrapib be the next big thing in coronary heart disease risk reduction?

Scientists are seeking ways to increase high-density lipoprotein (HDL) cholesterol to lower coronary heart disease (CHD). Emerging from this search is torcetrapib, a partial inhibitor of cholesteryl ester transfer protein. Via this mechanism, cholesteryl ester is prevented from being transferred to apolipoprotein B-containing lipoproteins and is retained in HDL particles, where ostensibly it may be delivered directly to the liver for elimination. Proof that this may reduce atherosclerotic vascular disease is provided by population studies of cholesteryl ester transfer protein (CETP) deficiencies and single nucleotide polymorphisms of CETP, and experiments in animal models treated with torcetrapib. Torcetrapib effectively raises HDL cholesterol when used alone and when added to background therapy with atorvastatin. The drug appears to be well tolerated. Large surrogate and survival outcome trials are underway to document its impact on CHD.

Anticholesteremic Agents↗